No Data
No Data
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment
Why Pfizer Inc. (PFE) Is One of the Best Stocks to Buy and Hold for 3 Years?
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts
Daily short sale tracking: Palantir's short volume increased by 51 million, with a short sale ratio of 23%
The Three-year Loss for Pfizer (NYSE:PFE) Shareholders Likely Driven by Its Shrinking Earnings